All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
Germany Vol.23 (pharmaceutical corporations: BioNTech)
上記リンク内に無い本日までのツイート
We provided an update on the potential timelines for the #COVID19 #vaccine candidate BNT162b2. We will seek approval only if the data provides a clear picture in three key areas: safety, efficacy, manufacturing quality. Read more in @WSJ by @bopanc. https://t.co/62njuhX3lu
— BioNTech SE (@BioNTech_Group) October 16, 2020
We are excited to welcome the latest addition to the BioNTech family: our colleagues in Marburg. The tech transfer is currently being made and we plan to start the production of potential #COVID19 vaccines in 2021. Welcome to #TeamBioNTech! pic.twitter.com/o9N26LmRoD
— BioNTech SE (@BioNTech_Group) November 2, 2020
One of the German #biotech firms working on a #CoronaVaccine, @BioNTech_Group, says results from study on effectiveness to come within next few days. Together with partner @pfizer will apply for FDA approval in 2 weeks. More on German vaccine development:https://t.co/cc92465OxM pic.twitter.com/YqwjNQds6O
— Germany Trade & Invest (@GTAI_com) October 30, 2020
https://twitter.com/InvestFlanders/status/1323176383582011394
Personalized #NeoantigenTherapy Plus #AntiPD1 | A Phase Ib Trial in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer | Lakshmi Srinivasan @BioNTech_Group @CellCellPress https://t.co/9NtpX0r8Bt | #2020_ReCapOct pic.twitter.com/2St8j5L624
— McHeyzer-Williams (@mmw_lmw) November 1, 2020
Engage with the community transforming the biotech sector at #BioIntegrates. Our one-day event will include interviews with Steve Bates, CEO, @BIA_UK and Sean Marett, Chief Business and Commercial Officer, @BioNTech_Group. Discover the full agenda: https://t.co/qynIgPU7rB pic.twitter.com/yJH4LzKuT2
— Life Science Integrates (@LSIntegrates) October 30, 2020
“The @UniofOxford/@AstraZeneca vaccine is expected to be one of the first from big #pharma to secure regulatory approval, along with @pfizer and @BioNTech_Group’s candidate" #ScienceNews #covid19news https://t.co/LgDPb8Eib4
— Life Science Rec. (@ScienceJobs) October 29, 2020
Comprehensive summary about the mRNA vaccine made in Mainz by Ugur, Özlem and the whole team of @BioNTech_Group and @tronmainz https://t.co/oqBicNHKrK
— Sebastian Boegel (@sebboeg) October 27, 2020
How a Little-known German Biotech Firm Founded by the Children of Turkish Immigrants Became a Leader in Global #Coronavirus Vaccine Race. My report via @WSJ: https://t.co/FcSyXVccnC
— Bojan Pancevski (@bopanc) October 22, 2020
https://twitter.com/en_germany/status/1317834581048020993
@pfizer will apply for EUA from @US_FDA soon after they achieve the safety milestone of their experimental vaccine (developed with @BioNTech_Group) in the third week of November: https://t.co/WUtZ1UGrg5#XerayaCapital #IndustryUpdates #COVID19 #Vaccine #Coronavirus pic.twitter.com/MQhAtL10oD
— Xeraya Capital (@xerayacapital) November 3, 2020
I continue to be #PfizerProud of all our colleagues, who delivered another strong quarter during these challenging times. The global phase 3 study for our #COVID19 vaccine candidate w/ @BioNTech_Group is ongoing at 150 sites with more than 42,000 participants enrolled. pic.twitter.com/ZCIzGMEDcJ
— AlbertBourla (@AlbertBourla) October 27, 2020
We are proud to organize the virtual @mrnaconference, the premier meeting destination for industry and academic professionals to explore the rapidly advancing science and business of #mRNA medicines. @BioNTech_Group @CureVacRNA @moderna_tx#eventplanning #vaccine #COVID19 pic.twitter.com/oKuuC0GpYA
— INTERPLAN Congress, Meeting & Event Management AG (@interplan_de) October 28, 2020
Richard B. Gaynor, MD, chair of the Accelerating Cancer Cures Advisory Committee, Damon Runyon board member, and President and Chief of Research and Development @BioNTech_Group U.S welcomes us to the virtual #CancerCures20 Symposium! pic.twitter.com/lArIzBNXKC
— Damon Runyon Cancer Research Foundation (@DamonRunyon) October 28, 2020
“@JNJNews plans to start testing its experimental #COVID19 #vaccine in youths aged 12 to 18 as soon as possible… Rival drugmaker @Pfizer has already begun testing the COVID-19 vaccine it is developing with Germany's @BioNTech_Group in children as young as 12.” #compliance https://t.co/PD9QxUCPag
— Mark Warner (@MAAWLAW) October 30, 2020
.@BioNTech_Group uses same mRNA technology as @moderna_tx. It never worked on anything, certainly not on vaccines, yet here we are.
Briefly discussed here: https://t.co/ccMuKcZYgi— Leonid Schneider (visit my site for Covid19 cures) (@schneiderleonid) October 27, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
We announced an agreement with #Japan for 120m doses of our mRNA-based vaccine candidate. This is part of our commitment to address the global health crisis together with @Pfizer as we hope it may help in bringing the world together at the #TokyoOlympics. https://t.co/YUmpvqELru pic.twitter.com/VcubAIgTvd
— BioNTech SE (@BioNTech_Group) July 31, 2020
Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan https://t.co/nR8eZ56zeB pic.twitter.com/yyabGBd1x2
— Reuters (@Reuters) October 20, 2020
Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan https://t.co/CPE5UL5WWR pic.twitter.com/iphKs1StYM
— Reuters (@Reuters) July 31, 2020
Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.https://t.co/jm6bN39Is7
— Hindustan Times (@htTweets) October 20, 2020
Pfizer, BioNTech start combined trials of #COVID19 vaccine candidate in Japanhttps://t.co/jm6bN2S73x pic.twitter.com/TiA3mzGXfn
— Hindustan Times (@htTweets) October 20, 2020
Japan to get 120 mn doses of #COVID19 vaccine from Pfizer, BioNTechhttps://t.co/dVvgeYAlhU pic.twitter.com/P8U5kvtWr7
— Hindustan Times (@htTweets) July 31, 2020
Russia says its secretive Covid-19 vaccine is “a Sputnik moment” – ready to be launched in less than 2 weeks.
As some countries develop their own, others are both making and buying vaccines, including Japan which is procuring 120M doses from Pfizer and BioNTech pic.twitter.com/pHRmIAQSGs
— TRT World (@trtworld) July 31, 2020
Today we announced an agreement with the Ministry of Health, Labor and Welfare in #Japan to supply 120M doses of our #COVID19 #vaccine candidate in collaboration with @BioNTech_Group, subject to regulatory approval: https://t.co/FBbQN3ciRF pic.twitter.com/U402NeO6WA
— Pfizer Inc. (@pfizer) July 31, 2020
We’re committed to helping governments have access to breakthroughs. Today we announced an agreement w/ Japan to supply, subject to regulatory approval, 120M doses of the mRNA-based COVID-19 vaccine candidate being co-developed by @Pfizer & @BioNTech_Group https://t.co/PmZEsrCRgZ
— AlbertBourla (@AlbertBourla) July 31, 2020
Pfizer and BioNTech agreed to provide Japan with 120 million doses of the Covid-19 vaccine they’re developing https://t.co/EGTGMDOuVl
— Bloomberg Technology (@technology) August 1, 2020
Pfizer, BioNTech to make 120M vaccine doses for Japan https://t.co/6JkbuzH5ug pic.twitter.com/ZYhPQd5dv9
— BNN Bloomberg (@BNNBloomberg) July 31, 2020
PFE Stock Down 0.5%, Pfizer and BioNTech to Supply Japan with 120M Doses of COVID-19 Vaccinehttps://t.co/UXUi8CUCgI pic.twitter.com/eYc2Wj14qd
— Coinspeaker (@coinspeaker) July 31, 2020
• Japan signs deal to secure 120 million dose of potential coronavirus vaccine, German pharmaceutical group BioNTech says https://t.co/XrAeG2tzpX
— ABS-CBN News (@ABSCBNNews) July 31, 2020
Pfizer $PFE, BioNTech $BNTX to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/Cww2CVC5jT pic.twitter.com/s2u8FoJU78
— Streetinsider.com (@Street_Insider) July 31, 2020
Pfizer, BioNTech score deal to supply 120M Covid-19 vaccine doses to Japan, writes @biotechvisigoth @medcitynews https://t.co/PSX9S2pMiz @BioNTech_Group $PFE $BNTX #COVID19
— MedCity News (@medcitynews) August 3, 2020
New post: Pfizer and BioNTech Supply Japan with 120 Million Doses of COVID-19 Vaccine Candidate BNT162 https://t.co/DLWtW6YYRt
— BiopharmaMASH (@bio_mash) August 1, 2020
Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/VajfZkzqfz @pfizer @BioNTech_Group More Transatlantic Life Science Business News at [LSUS] at https://t.co/HEEySVwfoy pic.twitter.com/PAdjZEeYAm
— [iito] Life Science (@iitoLifeScience) July 31, 2020
The #Covid19vaccine partnership of @BioNTech_Group and @pfizer inked its third supply pact in a week on Jul. 31. The #Japan government will take 120 million doses at an undisclosed price in the 2021 first half. It is the companies’ first #Asian agreement. https://t.co/jMHYIycNDk
— CHEManager International (@CHEManager_EU) August 4, 2020
US strikes $2.1bn #Covid19 vaccine deal with Sanofi $SAN and Glaxo $GSK, while Pfizer $PFE and BioNTech $BNTX to supply Japan with 120m vaccine candidate doses. More on the vaccine race in our podcast episode ➡️ https://t.co/LMsp4FXrx9 https://t.co/lOlbukINDP
— IGTV (@IGTV) July 31, 2020
Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Friday. | @AFP https://t.co/d9cryfWhNC
— Inquirer (@inquirerdotnet) July 31, 2020
Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said. https://t.co/crihB500gj
— Philstar.com (@PhilstarNews) August 1, 2020
Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Fridayhttps://t.co/v8o7oVWaA0 pic.twitter.com/M0IDFS0Egu
— AFP news agency (@AFP) July 31, 2020
Pfizer, BioNTech to supply 120 million doses of COVID-19 vaccine to Japan https://t.co/bqSgv5pZnW
— Business Today (@BT_India) July 31, 2020
#Japan signs deal with #BioNTech to secure 120 million doses of potential #coronavirus vaccine#TheNews
— The News (@thenews_intl) August 1, 2020
Pfizer, BioNTech to supply 120m doses of virus vaccine to Japan.https://t.co/G8kN9ZwzaV
— Nikkei Asia (@NikkeiAsia) July 31, 2020
Pfizer, BioNTech to supply 120 mil doses of experimental coronavirus vaccine to Japan: Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said… https://t.co/A5YL4MaTnk
— Japan Today News (@JapanToday) July 31, 2020
COVID-19 Vaccine Pipeline https://t.co/z9QJ2v4RBj via @kyodo_english #WHO @moderna_tx #NIAID @InovioPharma @BioNTech_Group #ClinicalResearch "Even if overseas vaccines have success and received special regulatory approval, the supply in Japan will be limited"
— ClinicalBid (@ClinicalBid) June 1, 2020
Japan signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech said Friday, July 31.
FULL STORY: https://t.co/eVEI6JXlcN pic.twitter.com/F8l7Ze6UUl
— Rappler (@rapplerdotcom) August 1, 2020
BioNTech says the first deliveries to Japan are planned for the first half of 2021. https://t.co/SjcHtrTMy2
— Rappler (@rapplerdotcom) August 1, 2020
Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for Xiidra. #TakedaPharmaceutical #Novartis #EMA #BionTech #StockMarketNews #Coronavirus #Xiidra #OperatingLoss #Asia@EMA_Newshttps://t.co/qgyUjrECut pic.twitter.com/8m4LRpX2I3
— iNVEZZ (@InvezzPortal) June 29, 2020
Boston Globe story yesterday on how small businesses in Central Square, #CambMA have been impacted by covid-19. https://t.co/ItouzHJizj. Biopharma companies in Central Sq incl Novartis, Takeda, Blueprint, Spero, Voyager, Beam, AbbVie, Fulcrum, Rheos, Neon/BioNtech, Intellia
— Pearl Freier (@PearlF) September 6, 2020
Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb
— Aspen Biosciences (@aspenbio) August 9, 2020
This week's EuroBiotech Report—Novo-Ablynx, Takeda-TiGenix, Scancell-BioNTech, Sanofi-Alnylam and Boehringer https://t.co/k5jkrKtv4M
— FierceBiotech (@FierceBiotech) January 11, 2018
